Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cytosorbents Corporation

Market Cap 24.33M 21.04M 19.38M 18.15M 34.04M 2.31B 34.55M 230M 89.21M 1.13B 91.32M 89.37M 3.9B P/E Ratio 2026 *
-2.16x
P/E Ratio 2027 * 13.3x
Enterprise Value 24.33M 21.04M 19.38M 18.15M 34.04M 2.31B 34.55M 230M 89.21M 1.13B 91.32M 89.37M 3.9B EV / Sales 2026 *
0.64x
EV / Sales 2027 * 0.52x
Free-Float
85.15%
Yield 2026 *
-
Yield 2027 * -
1 day+3.01%
1 week-18.07%
Current month-18.56%
1 month-36.54%
3 months-44.86%
6 months-43.69%
Current year-37.45%
1 week 0.37
Extreme 0.3695
0.48
1 month 0.37
Extreme 0.3695
0.61
Current year 0.37
Extreme 0.3695
0.84
1 year 0.37
Extreme 0.3695
1.39
3 years 0.37
Extreme 0.3695
4.29
5 years 0.37
Extreme 0.3695
9.8
10 years 0.37
Extreme 0.3695
14.95
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2008
Director of Finance/CFO 62 14/08/2024
President 68 28/04/2020
Director TitleAgeSince
Director/Board Member 77 25/07/2011
Director/Board Member 55 01/01/2009
Director/Board Member 65 13/11/2014
Date Insider Type Main position Quantity % Market Cap.
11-18Free

Chief Executive Officer

100,000 0.1593%
08/08/25Other

Director

22,000 0.0351%
08/08/25Other

Director

22,000 0.0351%
Change 5-day change 1-year change 3-year change Capi.($)
+3.01%-18.07%-63.32%-87.99% 24.33M
-1.33%-2.63%+13.05%-9.43% 177B
-0.45%-1.85%-21.31%+31.43% 146B
-0.38%-3.50%-12.03%-23.48% 128B
-0.55%-3.97%-52.81%-8.52% 70.11B
-0.76%-2.68%+12.77%+1.20% 49.38B
+0.67%-0.06%-25.59%-33.84% 44.23B
+0.22%-6.16%+8.45%+12.13% 36.59B
-1.17%-5.56%+2.74%+42.62% 35.32B
+1.04%+2.15%-11.20%-15.46% 29.35B
Average +0.10%-4.00%-14.92%-9.13% 71.6B
Weighted average by Cap. -0.41%-2.08%-9.05%-0.86%

Financials

2026 *2027 *
Net sales 38.26M 33.08M 30.47M 28.54M 53.52M 3.64B 54.33M 361M 140M 1.77B 144M 141M 6.13B 47.12M 40.74M 37.53M 35.15M 65.91M 4.48B 66.91M 445M 173M 2.18B 177M 173M 7.55B
Net income -11.74M -10.15M -9.35M -8.76M -16.42M -1.12B -16.67M -111M -43.04M -543M -44.06M -43.12M -1.88B 2.37M 2.05M 1.89M 1.77M 3.32M 226M 3.37M 22.39M 8.7M 110M 8.91M 8.72M 380M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
12/06/26 0.3998 $ +3.01% 440,276
11/06/26 0.3881 $ -5.57% 441,186
10/06/26 0.4110 $ -2.72% 76,842
09/06/26 0.4225 $ +2.00% 94,802
08/06/26 0.4142 $ -9.76% 43,639
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3998USD
Average target price
2.875USD
Spread / Average Target
+619.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!